Aortic Repair Devices – Market Insights – Latin America

The Latin American aortic repair device market is expected to expand modestly over the forecast period. Market growth will be supported by the launch and increasing adoption of new devices that allow the endovascular treatment of more complex aneurysms. The market contribution of aortic stent grafts to the overall aortic repair device market will further increase in the following years, particularly for TAA and TAAA, as more branched and hybrid grafts become available. However, cost constraints faced by Latin American healthcare system and ASP erosion of higher-priced aortic stent grafts will limit the pace of the market growth to some extent.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for aortic repair devices in Europe from 2019 to 2032.

Aortic aneurysm repair in Latin America by endovascular and hybrid approach will increase during the forecasted period.

Which types of aortic stent grafts will see the highest increase in unit sales through 2032?

How does the penetration of different procedure types differ across the Latin American countries vary?

How changes in relative procedure penetration will affect the relative contributions of each device type?

The aortic stent graft market is characterized by innovation, with companies launching products that enable to treat complex aortic aneurysms.

Which products are expected to enter the Latin American aortic stent graft market?

What impact will the launch of next-generation stent grafts—namely branched, fenestrated or hybrid endografts—have over the competitive landscape?

Which indications will these products cover and how will this affect procedure volumes?

To what extent will these launches affect other products such as surgical grafts or endovascular anchors?

There remains a number of unmet needs for treating aortic aneurysms.

Will hybrid grafts become available for other indications than the aortic arch?

Will fenestrated endografts become available for other indications than the juxtarenal aorta?

Will endografts that enable endovascular repair of ascending aorta become available?

The increasing presence of risk factors will support the growth of procedure volumes, although poor economic conditions will somewhat hinder market growth.

How do economic conditions vary by country?

How will adoption of aortic repair devices differ by country and device type?

Which indications will see the greatest procedure volume growth?

Table of contents